Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Latanoprost + Brinzolamide Fixed Combination in Glaucoma or Ocular Hypertension
NCT01721707Phase 3Withdrawn
- Sponsor
- Adapt
- Start
- Dec 2012
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brinzolamide + latanoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Adapt. Primary endpoint: Intraocular Pressure at Month 3. Planned start Dec 2012; status: withdrawn.
02
Drugs
brinzolamide + latanoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT01721707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01721707.